Quick Answer
Nurix Therapeutics, Inc. reported Stockholders Equity of $538.75 million for the year ending 2025.
- Nurix Therapeutics, Inc. showed an increase of +2.2% in Stockholders Equity from 2024 to 2025.
- This data is from Nurix Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on January 28, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$39.36 million | Q2 2019: -$42.20 million | Q3 2019: -$44.44 million | Q1 2020: -$69.80 million | Q2 2020: -$61.53 million | Q3 2020: $307.62 million | Q1 2021: $270.13 million | Q2 2021: $398.18 million | Q3 2021: $375.22 million | Q1 2022: $305.92 million | Q2 2022: $266.74 million | Q3 2022: $342.55 million | Q1 2023: $274.05 million | Q2 2023: $259.92 million | Q3 2023: $233.82 million | Q1 2024: $168.75 million | Q2 2024: $370.69 million | Q3 2024: $376.86 million | Q1 2025: $480.92 million | Q2 2025: $447.60 million | Q3 2025: $372.25 million.
- Over the full 8 years of available data (2018 to 2025), Nurix Therapeutics, Inc.'s Stockholders Equity has grown by 1,562.1%.
- Historical annual values: Fiscal year 2025: $538.75 million | Fiscal year 2024: $526.99 million | Fiscal year 2023: $200.49 million | Fiscal year 2022: $303.70 million | Fiscal year 2021: $342.30 million | Fiscal year 2020: $290.27 million | Fiscal year 2019: -$57.71 million | Fiscal year 2018: -$36.85 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: